Administration of somatostatin analogs along with insulin to people with T1D suppresses glucagon levels, improves postprandial glucose responses/diurnal glucose fluctuations, reduces insulin requirements and peripheral hyperinsulinemia, increases the effects of insulin on the stimulation of glucose disposal/suppression of EGP by more than 2-fold, reduces NEFA/glycerol levels, and increases nonoxidative glucose metabolism (162-165). Here, INS is linked to hyperinsulinism.